Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Steve Eppler"'
Autor:
Rebecca A. Moss, Janice M. Mehnert, Blase Polite, Mark J. Ratain, Amy Peterson, Daniel V.T. Catenacci, Ihsan Nijem, Surinder Kaur, Shuang Bai, Priti Hegde, Steve Eppler, Wei Yu, John Bothos, Premal Patel, Ravi Salgia
PDF file - 88K, Table S1. Treatment-related adverse events across all dosing cohorts in Phase Ia escalation and expansion, and Phase Ib. Table S2. Most commonly reported adverse events regardless of relationship to study drug.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19f7f6584b5adf11cb2797c9f5c4ef90
https://doi.org/10.1158/1078-0432.22451313
https://doi.org/10.1158/1078-0432.22451313
Autor:
Rebecca A. Moss, Janice M. Mehnert, Blase Polite, Mark J. Ratain, Amy Peterson, Daniel V.T. Catenacci, Ihsan Nijem, Surinder Kaur, Shuang Bai, Priti Hegde, Steve Eppler, Wei Yu, John Bothos, Premal Patel, Ravi Salgia
Purpose: This first-in-human study evaluated the safety, immunogenicity, pharmacokinetics, and antitumor activity of onartuzumab, a monovalent antibody against the receptor tyrosine kinase MET.Experimental Design: This 3+3 dose-escalation study compr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f7df0c5a4ee8a3a8ac96c8507697062
https://doi.org/10.1158/1078-0432.c.6522162.v1
https://doi.org/10.1158/1078-0432.c.6522162.v1
Autor:
Maria Anderson, Steve Eppler, Bruce McCall, Eric Wakshull, Tony Pourmohamad, Colin D. Weekes, Ina Rhee, Weilan Ye, Alberto Bessudo, Anna Capasso, Rupal Desai, Priti S. Hegde, Mahrukh Huseni, Jill Fredrickson, Quyen Shon-Nguyen, Lee S. Rosen, Kit Man Wong
Publikováno v:
Cancer Chemotherapy and Pharmacology. 82:339-351
MINT1526A is a monoclonal antibody that blocks the interaction of integrin alpha 5 beta 1 (α5β1) with its extracellular matrix ligands. This phase I study evaluated the safety and pharmacokinetics of MINT1526A with or without bevacizumab in patient
Autor:
Matthew Chapple, Luna Musib, Brian Dean, Sarah Burke, Yuzhong Deng, Edna F. Choo, James Johnson, Steve Eppler
Publikováno v:
Journal of Chromatography B. 972:117-123
Inhibition of MAP/ERK kinase (MEK) is a promising strategy to control the growth of tumors that are dependent on aberrant signaling in the MEK pathway. Cobimetinib (GDC-0973) (S)-[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-((S)-3-hydroxy-3-
Autor:
Mark J. Dresser, Iris T. Chan, Edna F. Choo, Isabelle Rooney, Luna Musib, Yuzhong Deng, Steve Eppler
Publikováno v:
Molecular Pharmaceutics. 10:4046-4054
Cobimetinib is a potent and highly selective inhibitor of MEK1/2. Since cobimetinib exhibited absorption variability in cancer patients, a series of single-dose studies in healthy subjects were conducted to determine absolute bioavailability and eluc
Publikováno v:
Clinical pharmacokinetics. 55(11)
Cobimetinib is eliminated mainly through cytochrome P450 (CYP) 3A4-mediated hepatic metabolism in humans. A clinical drug–drug interaction (DDI) study with the potent CYP3A4 inhibitor itraconazole resulted in an approximately sevenfold increase in
Autor:
Helen Winter, Mark Stroh, S Dayog, Steve Eppler, Mathilde Marchand, SL Teng, O Abidoye, Jane Ruppel, Jin Yan Jin, Rene Bruno, Laurent Claret, Sandhya Girish, WT Lin
Publikováno v:
Clinical pharmacology and therapeutics. 102(2)
Atezolizumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting human programmed death-ligand 1 (PD-L1), is US Food and Drug Administration (FDA) approved in metastatic urothelial carcinoma (MUC) and is being investigated in various
Autor:
Gerhard F. Weinbauer, Anu Vaidyanathan, Banmeet S. Anand, Steve Eppler, Joseph Beyer, Kathleen McKeever
Publikováno v:
Toxicological Sciences. 119:116-125
Rituximab is a chimeric murine/human-engineered immunoglobulin (Ig) G1 anti-CD20 monoclonal antibody, selectively depleting CD20-expressing cells in peripheral blood and lymphoid tissues. As part of the rituximab registration-enabling program for rhe
Publikováno v:
Cancer Chemotherapy and Pharmacology. 62:779-786
To characterize the population pharmacokinetics of bevacizumab and the influence of demographic factors, disease severity, and concomitantly used chemotherapy agents on it's pharmacokinetic behavior.Data from eight clinical trials with bevacizumab ad
Autor:
Marta Hamilton, Bert L. Lum, Julie L. Wolf, Ashok Rakhit, Steve Eppler, Rene Bruno, Jian-Feng Lu
Publikováno v:
Clinical Pharmacology & Therapeutics. 80:136-145
Objective Our objective was to assess the pharmacokinetics of erlotinib in a large patient population with solid tumors, identify covariates, and explore relationships between exposure and safety outcomes (rash and diarrhea) in patients with non-smal